Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

10,706 total articles

Olin: Buy the Post-Shock Dip — Plant Trouble Looks Temporary

Olin: Buy the Post-Shock Dip — Plant Trouble Looks Temporary

Olin's share price has been punished by an unplanned vinyl chloride monomer plant shutdown and legal noise around the Huntsman merger. The disruption is a one-time cash hit of about $40 million to Q2 adjusted EBITDA with an estimated $20 million follow-through in Q3. At $17.29, the stock is trading near its 52-week low, yields 4.6%, and still gener…

Meta: Monetize Idle GPUs — Buy the Dip, Lease the Upside

Meta: Monetize Idle GPUs — Buy the Dip, Lease the Upside

Meta owns one of the largest AI compute footprints on the planet. If management moves aggressively to rent spare GPU capacity through inference/finetune marketplaces and third-party cloud deals, revenue upside and margin expansion can follow quickly. This is a mid-term trade: enter at $450, stop $390, target $540 on a 45 trading day horizon, with a…

Buy CLOV: AI-First Medicare Advantage at a Reasonable Growth Multiple

Buy CLOV: AI-First Medicare Advantage at a Reasonable Growth Multiple

Clover Health is an actionable long thanks to accelerating Medicare Advantage membership, demonstrable AI-driven care improvements, improving free cash flow and a valuation that prices growth modestly. This trade idea lays out a mid-term plan centered on enrollment catalysts and recurring care-management economics while flagging regulatory, data an…

Symbotic: eFY2027 Revenue Inflection Is Lining Up — Strong Buy

Symbotic: eFY2027 Revenue Inflection Is Lining Up — Strong Buy

Symbotic is a hardware-led automation platform with a $22.3 billion backlog, 23% YoY revenue growth in Q2 2026, a material free cash flow stream, and recent software acquisitions that convert lumpy installations into higher-margin recurring value. We view the company as primed for an eFY2027 inflection in revenue conversion and margin expansion; in…

AMC: Trade the News, But Watch the Share Count

AMC: Trade the News, But Watch the Share Count

AMC is trading at $2.66 with clear operational momentum from stronger attendance and a cleaner debt profile after recent refinancing. The stock can rally near-term, but the dominant risk remains share issuance. This trade sets a defined entry, stop and target while emphasizing active monitoring of outstanding shares and any new equity deals.

Ondas: Real Top-Line Momentum — Trade It With Tight Risk Control

Ondas: Real Top-Line Momentum — Trade It With Tight Risk Control

Ondas (ONDS) is growing fast: recent contract wins and an acquisition lift 2026 revenue targets well into the hundreds of millions, yet the company remains unprofitable and cash flow negative. For traders willing to accept volatility, a defined long trade with a clear stop and target offers attractive asymmetric upside while limiting downside if ex…

Sezzle Anywhere + Sezzle Cash: Hidden Operating Leverage, Visible Upside

Sezzle Anywhere + Sezzle Cash: Hidden Operating Leverage, Visible Upside

Sezzle's merchant-facing Sezzle Anywhere checkout and consumer-facing Sezzle Cash product create a path to disproportionate EBITDA growth as volumes scale. The market appears to be underestimating operating leverage from higher take rates, fixed-cost absorption, and cross-sell between products. This trade targets the re-rating that should follow ac…

Arteris Building a Base Near $23 — Setup for a Mid-Stage Breakout

Arteris Building a Base Near $23 — Setup for a Mid-Stage Breakout

Arteris (AIP) has pulled back from its 52-week highs and is carving a consolidation base around $23. The company's steady wins in automotive and cybersecurity IP, plus a recent acquisition and expanded Arm partnership, give a fundamental backdrop for a swing trade. Valuation is lofty vs. current profitability, so the trade is price-action driven wi…

Royalty Pharma: A Reliable Cash Engine the Market Still Misreads

Royalty Pharma: A Reliable Cash Engine the Market Still Misreads

Royalty Pharma (RPRX) is a cash-generating royalty vehicle with a diversified portfolio of commercial drugs and a growing development pipeline. At roughly $62 per share, the stock trades with an enterprise value to free cash flow of ~12x despite steady FCF of nearly $3.0B and visible catalysts (Asia expansion, Teva collaboration, new translational …

Nebius: Front-Loading Exposure to the AI Buildout With a Tactical Long

Nebius: Front-Loading Exposure to the AI Buildout With a Tactical Long

Nebius (NBIS) is an infrastructure-first play in the next wave of cloud AI. The company just reported explosive top-line growth, materially shortened contract payback, and multi-billion-dollar customer commitments. That combination makes NBIS a high-upside tactical long over the next 45 trading days, but the stock carries elevated valuation and cap…